IMA ImageneBio, Inc.
ImageneBio, Inc. (IMA) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.99 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -22.3% since its last earnings release on November 9, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About ImageneBio, Inc.
Inmagene Biopharmaceuticals is a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory diseases. The company's lead asset includes IMG-007, a nondepleting anti-OX40 monoclonal antibody. Inmagene Biopharmaceuticals, formerly known as Ikena Oncology Inc., is based in SAN DIEGO.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.